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Background: Few studies thus far have compared head-to-head different non-myelooablative conditioning regimens
for allogeneic hematopoietic cell transplantation (allo-HCT).
Methods: Here, we report the results of a phase II multicenter randomized study comparing non-myeloablative allo-HCT
from HLA-identical siblings (n = 54) or from 10/10 HLA-matched unrelated donors (n = 40) with either fludarabine plus
2 Gy total body irradiation (Flu-TBI arm; n = 49) or 8 Gy TLI + anti-thymocyte globulin (TLI-ATG arm; n = 45) conditioning.
Results: The 180-day cumulative incidences of grade II-IV acute GVHD (primary endpoint) were 12.2% versus 8.9% in
Flu-TBI and TLI-ATG patients, respectively (P = 0.5). Two-year cumulative incidences of moderate/severe chronic GVHD
were 40.8% versus 17.8% in Flu-TBI and TLI-ATG patients, respectively (P = 0.017). Five Flu-TBI patients and 10 TLI-ATG
patients received pre-emptive DLI for low donor chimerism levels, while 1 Flu-TBI patient and 5 TLI-ATG patients
(including 2 patients given prior pre-emptive DLIs) received a second HCT for poor graft function, graft rejection, or
disease progression. Four-year cumulative incidences of relapse/progression were 22% and 50% in Flu-TBI and TLI-ATG
patients, respectively (P = 0.017). Four-year cumulative incidences of nonrelapse mortality were 24% and 13% in Flu-TBI
and TLI-ATG patients, respectively (P = 0.5). Finally, 4-year overall (OS) and progression-free survivals (PFS) were 53% and
54%, respectively, in the Flu-TBI arm, versus 54% (P = 0.9) and 37% (P = 0.12), respectively, in the TLI-ATG arm.
Conclusions: In comparison to patients included in the Flu-TBI arm, patients included in the TLI-ATG arm had lower
incidence of chronic GVHD, higher incidence of relapse and similar OS.
Trial registration: The study was registered on ClinicalTrial.gov (NCT00603954) and EUDRACT (2010-024297-19).
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Allogeneic hematopoietic cell transplantation (allo-HCT)
following non-myeloablative conditioning is increasingly
used as treatment for hematological malignancies in older
patients or those with medical comorbidities [1,2]. This
approach relies mostly on immune-mediated graft-versus-
tumor effects for tumor eradication [3,4]. One of the most* Correspondence: f.baron@ulg.ac.be
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unless otherwise stated.widely used non-myeloablative conditioning associates flu-
darabine (90 mg/m2 total dose) and 2 Gy total body irradi-
ation (TBI) [3-10]. This regimen can be safely performed
in an outpatient setting but is associated with a relatively
high incidence of graft-versus-host disease (GVHD) [3-7].
In an effort to prevent GVHD, the Stanford group has
developed another non-myeloablative conditioning that
combines total lymphoid irradiation (TLI, 8 Gy total
dose) with ATG (7.5 mg/kg Thymoglobulin® total dose)
[11-15]. This approach allowed sustained engraftment
with a low incidence of GVHD through polarization ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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transplantation because they are relatively resistant to
the conditioning) towards a Th2 phenotype [16].
As these two promising regimens had never been com-
pared head-to-head, the Belgian Hematological Society
(BHS)-transplantation committee initiated a phase II mul-
ticenter randomized study comparing non-myeloablative
allo-HCT with either fludarabine plus 2 Gy TBI (Flu-TBI
arm) or 8 Gy TLI + ATG (TLI-ATG arm) conditioning.
Results
Patients
One hundred and seven patients were randomized in
the Flu-TBI (n = 55) or TLI-ATG (n = 52) arms between
January 2008 and March 2011 in one of the 9Table 1 Patient characteristics
F
Number of patients 4
Patient age, Median (range), years 6
Patient gender (male/female), # of patients 3
Donor type; # of patients
HLA-identical sibling/10/10 HLA-allele matched URD 2
Donor age, Median (range), years 5
Female donor to male recipient, # of patients 1
CMV-serostatus (donor/patient), # of patients
−/− 1
−/+ 1
+/− 8
+/+ 1
Disease at transplantation; # of patients
Acute myeloid leukemia 1
Acute lymphoblastic leukemia 4
Chronic lymphocytic leukemia 7
Myelodysplatic syndrome/ 9
Chronic myelomonocytic leukemia 2
Multiple myeloma 3
Myeloproliferative disorder 2
Non-Hodgkin lymphoma 5
Waldenström disease 0
Disease risk [17]: low/standard/high; # of patients 1
Comorbidity (HCT-CI score) [18]; median (range) 1
Performance status: 0/1/2; # of patients 1
Prior autologous HCT; # of patients 1
Graft composition (× 106/kg recipient)
CD34; median (range) 5
CD3; median (range) 3
*the CMV serostatus of one recipient (CMV sero-positive donor) is missing; †the CM
when only the % of patients with high-risk disease was compared.participating centers (Additional file 1: Table S1). Thirteen
patients (6 in the Flu-TBI and 7 in the TLI-ATG arm)
were excluded from analysis because they did not meet
the inclusion criteria at the time of the start of the condi-
tioning (disease relapse before the start of the condition-
ing (n = 5), ineligible for further irradiation (n = 3), donor
refusal to give peripheral blood stem cells (PBSC) (n = 2),
HLA-mismatched donor (n = 2), and poor PS precluding
transplantation (n = 1)). One patient randomized in the
Flu-TBI arm received the TLI-ATG conditioning (and was
analyzed in intention to treat in the Flu-TBI arm). Thus,
the analysis includes data from 94 patients randomized to
the Flu-TBI (n = 49) or TLI-ATG (n = 45) arm (Table 1).
The 2 groups were well balanced with the exception of
higher numbers of transplanted CD34+ cells (P = 0.02)lu–TBI TLI-ATG p value
9 45
0 (38–73) 59 (32–71) 0.2
5/14 29/16 0.5
9/20 25/20 0.8
1 (19–66) 46 (19–69) 0.6
2 9 0.6
0.3
2 13†
7 12
3
1* 16
7 16
1
3
8
3
2
1
10
1
5/24/10 12/18/15 0.4‡
(0–8) 0 (0–6) 0.2
7/30/2 22/21/2 0.4
0 6 0.4
.6 (2.1–11.5) 6.6 (2.4–11.8) 0.02
34 (76–647) 291 (73–834) 0.8
V serostatus of one recipient (CMV sero-negative donor) is missing; ‡P = 0.17
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high disease risk according to the Kahl et al. classification
[17] (P = 0.17) in the TLI-ATG arm. Results were analyzed
as of 3 October 2013. Median follow-up for surviving
patients was 45 (range, 19–65) months.
Protocol deviation
In the Flu-TBI arm, major protocol deviations included
the use of cyclosporine instead of tacrolimus for GVHD
prophylaxis (n = 5), incorrect administration of fludara-
bine (4 days instead of 3 days (n = 1) or incorrect schedule
of fudarabine or TBI administration (n = 4; including 2 of
the 4 patients given cyclosporine for GVHD prophylaxis),
or administration of the TLI-ATG conditioning instead of
the Flu-TBI regimen (n = 1). In the TLI-ATG arm, major
protocol deviations occurred in 9 patients and included
incorrect timing of ATG administration (n = 5; too close
to transplantation with the last ATG dose on day −6
(n = 1), −5 (n = 2), or–3 (n = 2)), incorrect dose of ATG
(n = 3; 10 mg/kg total dose (n = 2), 3 mg/kg total dose
(n = 1)), cyclosporine instead of tacrolimus (n = 2), and
8 Gy TLI administered in 9 fractions instead of 10 (n = 1).
Engraftment
In comparison to Flu-TBI patients, TLI-ATG patients
had significantly lower absolute neutrophil counts on
day 0, lower absolute lymphocyte counts from day 0 to
day 42, lower platelet counts on days 0 and 7, and lower
hemoglobin levels on day 0 and from day 21 to day 180Figure 1 Hematologic recovery in the 2 groups the first year after tra
C) hemoglobin (Hb) levels and D) platelet levels.after transplantation (Figure 1). Accordingly, 30 of 49
Flu-TBI patients versus 38 of 45 TLI-ATG patients were
given at least 1 red blood cell transfusion the first
100 days after transplantation (P = 0.02), while 14 of 49
Flu-TBI patients versus 26 of 45 TLI-ATG patients were
given at least 1 platelet transfusion during that period
(P = 0.006).
Donor T-cell chimerism levels were lower in the TLI-
ATG arm on days 180 and 365 after HCT, while TLI-ATG
patients had also lower marrow chimerism levels on days
40 and 180 after allo-HCT (Figure 2). Three patients in
the Flu-TBI arm and 4 patients in the TLI-ATG arm had
graft rejection (defined as ≤ 5% donor chimerism in T
cells, total white blood cells and/or total bone marrow
cells). Further, 5 Flu-TBI patients and 10 TLI-ATG pa-
tients received pre-emptive DLI for low donor chimerism
levels (another TLI-ATG recipient received pre-emptive
DLI for relapse prevention), while 1 Flu-TBI patient and 5
TLI-ATG patients (including 2 given prior pre-emptive
DLIs) received a second HCT for poor graft function, graft
rejection, or disease progression (P = 0.1).GVHD
Before day 180, 6/49 Flu-TBI patients had grade II (n = 4),
grade III (n = 1) or grade IV (n = 1) acute GVHD while 4/
45 TLI-ATG patients had grade II (n = 3) or IV (n = 1, oc-
curring after pre-emptive DLI for poor chimerism) acute
GVHD. The 180-day cumulative incidences of grade II-IVnsplantation. A) Neutrophil count (ANC), B) lymphocyte count (ALC),
Figure 2 Chimerism levels in Flu-TBI (black boxes) and TLI-ATG (white boxes) patients. A) T cell chimerism levels, and B) Bone marrow
(BM) chimerism levels.
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ATG patients, respectively (P = 0.508) (Figure 3A).
Two-year cumulative incidences of moderate/severe
chronic GVHD were 40.8% versus 17.8% in Flu-TBI and
TLI-ATG patients, respectively (P = 0.0165) (Figure 3B).
In multivariate analysis, TLI-ATG conditioning (HR = 0.3,
95% confidence interval (CI): 0.1-0.8, P = 0.010), and
transplantation from a HLA-identical sibling donor
(HR = 0.5, 95% CI: 0.2-1.0; P = 0.0495) were associated
with a lower incidence of moderate/severe chronic GVHD,
while female donor to male recipient was associated
with a higher incidence of moderate/severe chronic
GVHD (HR 3.8, 95% CI: 1.7-8.5, P = 0.001).
Infections
Nineteen of 49 Flu-TBI patients (39%) versus 25 of 45 TLI-
ATG patients (56%) had a least one episode of bacterial
infection the first 100 days after transplantation (P = 0.15).
For fungal infections, the figures were 3 of 45 (6%) and
7 of 45 (16%), respectively (P = 0.19). Finally, among
CMV-seropositive patients and/or donors, the 100-day
cumulative incidence of CMV reactivation was 31% in
Flu-TBI patients versus 47% in TLI-ATG patients (P = 0.12;
Figure 3C).
Relapse, nonrelapse mortality and survival
Four-year cumulative incidences of relapse/progression
were 22% and 50% in Flu-TBI and TLI-ATG patients, re-
spectively (P = 0.017; Figure 3D). The difference remained
statistically significant in multivariate analysis (HR = 2.3,
95% CI 1.1-4.7, P = 0.02). Four-year cumulative incidences
of NRM were 24% and 13% in Flu-TBI and TLI-ATG
patients, respectively (P = 0.5).
Four-year OS and PFS were 53% and 54%, respectively, in
the Flu-TBI arm, versus 54% (P = 0.9) and 37% (P = 0.12),
respectively, in the TLI-ATG arm (Figure 3 E-F). In multi-
variate analyses, there was a trend for lower PFS in patients
transplanted for high-risk disease (HR = 2.0, 95% CI: 1.0-
4.1, P = 0.07), while higher HCT-CI scores [18] predictedfor lower OS (HR= 1.2, 95% CI: 1.0-1.4, P = 0.02). Causes
of death are listed in the Table 2.
OS and PFS were further recalculated as of December
2014. With a median follow-up for surviving patients of
58.5 months, 5-year OS and PFS were 53% and 50%
respectively in Flu-TBI patients, versus 55% (P = 0.96)
and 37% (P = 0.14), respectively, in TLI-ATG patients.
Discussion
This multicenter randomized phase II study compared
two non-myeloablative conditioning regimens. Main ob-
servations were that although the incidence of grade II-IV
acute GVHD was comparable in both arms, the TLI-ATG
regimen was associated with a significantly lower inci-
dence of moderate/severe chronic GVHD. The similar
incidence of acute GVHD in the 2 arms was due to a
lower than anticipated incidence of grade II-IV acute
GVHD in the TBI arm, perhaps due to a relatively high
dose of MMF used in sibling recipients, and to the rela-
tively high targeted tacrolimus levels the first 100 days
after transplantation [19]. In contrast, the low incidence of
moderate/severe chronic GVHD in TLI-ATG patients is
consistent with prior publications from the Stanford group
[11,12], while the 40% incidence of chronic GVHD in
Flu-TBI patients is also in agreement with observation
from the Seattle consortium [8,10]. Although previous
studies have demonstrated a lower incidence of chronic
GVHD in patients given ATG [20-22], the low inci-
dence of chronic GVHD observed in current TLI-ATG
recipients is unlikely due to ATG only, given that other
studies have demonstrated that median serum active
ATG levels the day of transplantation after TLI-ATG
regimen are < 5 mg/L [11,23], well below the threshold
associated with lower incidence of chronic in a recent
study by Chawla et al. (8.12 mg/L) [24].
The TLI-ATG regimen was also associated with a higher
incidence of relapse, although these results should be
taken with caution given the heterogeneity of diagnoses
and status at transplantation in our study. Nevertheless,
Figure 3 Transplantation outcomes. A) 180-day cumulative incidence of grade II-IV acute GVHD. B) 5-year cumulative incidence of moderate/
severe chronic GVHD. C) 100-day cumulative incidence of CMV reactivation. D) 5-year cumulative incidence of progression. E) 5-year progression-free
survival. F) 5-year overall survival. Broken line: fludarabine (90 mg/m2) plus 2 Gy total body irradiation; continuous line = 8 Gy total lymphoid irradiation
plus ATG thymoglobulinR (7.5 mg/kg).
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Table 2 Causes of death
Flu-TBI (n = 22/49) TBI-ATG (n = 19/45)
Relapse/progression* 10 13
Infection 5 3
Acute GVHD 1 2†
Chronic GVHD 2 0
Acute respiratory
distress syndrome
1 0
Alveolar hemorrhage 1 0
Epilepsy 1 0
Second malignancy 1 0
Hemolytic anemia 0 1
*defined as every death occurring after relapse/progression; †including one
patient after pre-emptive DLI for poor chimerism.
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patients in the current study (50% at 4 years) is compar-
able to what has been observed by the Stanford group
(53% at 4-year) in a larger cohort of patients [12]. This
observation is also in accordance with prior studies that
observed higher risks of relapse with lower donor T-cell
chimerism [3,12,25,26] and absence of chronic GVHD
[3,4,27,28]. This higher incidence of relapse in TLI-ATG
patients translated into a trend for lower PFS, but, import-
antly, OS was identical in the 2 arms.
Conclusions
In summary, in comparison to patients included in the
Flu-TBI arm, patients included in the TLI-ATG arm had
lower incidence of chronic GVHD, higher incidence of
relapse, and similar OS. Current efforts are focusing at
decreasing the incidence of GVHD without affecting the
relapse incidence in Flu-TBI patients (ClinicalTrial.gov #
NCT01231412 & NCT01428973), and at preventing
relapse in patients with low donor chimerism levels early
after transplantation in TLI-ATG patients (ClinicalTrial.
gov # NCT01392989).
Methods and study design
Conditioning regimen and transplant procedure
In the Flu-TBI arm, conditioning consisted of fludarabine
30 mg/m2 on days −4, −3 and −2, followed by a singe dose
of 2 Gy TBI administered on day 0 (TBI administration
on day −1 was also allowed). In the TLI-ATG arm,
conditioning consisted of 8 Gy TLI (80 cGy daily,
starting 11 days before transplantation, until a total of
10 doses (8 Gy) had been delivered) and ATG (Thymo-
globulin®, Genzyme) given i.v. at a dose of 1.5 mg/kg/d
from days −11 through −7. In both regimens postgraft-
ing immunosuppression included mycophenolate mofetil
(MMF) administered orally from the evening of day 0
through day 28 (HLA-identical sibling donors) or day 42
(10/10 HLA allele matched unrelated donors) at a dose of15 mg/kg t.i.d., and tacrolimus administered orally from
day −3. Tacrolimus doses were adapted to achieve whole
blood through levels between 15 and 20 ng/ml the first
28 days and between 10–15 ng/ml thereafter. Full doses
were given until day 100 (sibling recipients) or 180 (unre-
lated recipients). Doses were then progressively tapered to
be discontinued (in the absence of GVHD) by day 180
(sibling donors) or 365 (unrelated donors). Acute GVHD
and late acute GVHD were graded using international
criteria, while chronic GVHD was graded according to
the NIH criteria [29].
Study design
The study planned the inclusion of 100 patients. The
study was approved by the Ethics Committee of the Uni-
versity of Liège (central ethic committee) and by the ethics
committee of the participating centers. The study was reg-
istered on ClinicalTrial.gov (NCT00603954; https://www.
clinicaltrial.gov/ct2/show/NCT00603954?term=NCT0060
3954&rank=1) and EUDRACT (2010-024297-19; https://
www.clinicaltrialsregister.eu/ctr-search/trial/2010-024297-
19/BE).
Inclusion and exclusion criteria
Inclusion criteria were: 1) Hematological malignancies
confirmed histologically and not rapidly progressing; 2)
Theoretical indication for a myeloablative allo-HCT, but
not feasible because of age, patient refusal, or comorbid-
ity, or planned tandem autologous/allogeneic HCT; 3)
age ≤ 75 years of age; 4) HLA-identical sibling donor or
10/10 HLA –A, −B, −C, −DRB1, −DQB1 allelic matched
related or unrelated donor fit to (and willing to) give G-
CSF mobilized peripheral blood stem cells (PBSC), and 5)
Signed informed written consent. Main exclusion criteria
included: 1) HIV positivity; 2) Non-hematological malig-
nancy(ies) (except non-melanoma skin cancer) < 3 years
before allo-HCT; 3) Life expectancy severely limited by
disease other than malignancy; 4) Administration of cyto-
toxic agent(s) for “cytoreduction” within three weeks prior
to initiating the non-myeloablative transplant conditioning
(Exceptions were hydroxyurea and imatinib mesylate); 5)
CNS involvement with disease refractory to intrathecal
chemotherapy; 6) Terminal organ failure, except for renal
failure; 7) Uncontrolled infection; 8) Karnofsky Perform-
ance Score <70%; and 9) Previous radiation therapy pre-
cluding the use of 2 Gy TBI or 8 Gy TLI.
Endpoints
The primary endpoint was the 180-day incidence of
grade II-IV acute GVHD. Secondary endpoints included:
1) hematopoietic (whole blood and T-cell chimerisms)
engraftment and incidence of graft rejection; 2) Incidence
of grade I-IV and III-IV acute GVHD; 3) Incidence of
chronic GVHD; 4) Quality and timing of immunologic
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[23]); 5) Incidences of infections; and 6) incidence of
relapse (RI), nonrelapse mortality (NRM), progression-
free survival (PFS) and overall survival (OS).
Randomization
Patients were randomized 1/1 according to a random-
ization list obtained with the Graphpad QuickCalcs
software. Randomization was stratified by center. Randomi-
zations were carried out by a data manager or by an investi-
gator from the University of Liège.
Statistical analyses
Graft composition, hematological recovery and chimerism
levels among groups were compared using the Mann–
Whitney test. Comparison of the number of patients who
developed at least one infectious episode in the 2 groups
was performed using the Fisher’s exact test. OS and PFS
were estimated by the Kaplan-Meier method. Cumulative
incidence curves were used for GVHD, CMV infection,
and relapse incidences (RI) with death as a competitive
risk, and for nonrelapse mortality (NRM) with relapse as a
competitive risk. Patients given a second allogeneic HCT
were censured for GVHD analyses. Multivariate Cox
models were fit for analyzing acute and chronic GVHD,
PFS, OS and RI. Potential factors examined in the Cox
models for GVHD included study arm, female donor to
male recipient versus other gender combinations, related
versus unrelated donor, donor and recipient CMV-
serostatus, and patient age. Factors analyzed for OS,
PFS, NRM and RI included study arm, female donor to
male recipient versus other gender combinations, related
versus unrelated donor, patient age, disease risk of relapse
(as defined by Kahl et al. [30]), and HCT-CI score [18] (only
for NRM, OS and PFS). There were stopping rules (in each
group separately) for graft rejection > 15% at day 180, and
for NRM> 35% at day 180, while a planned interim analysis
was performed after 60 patients. Results were analyzed as
of 3 October 2013. Statistical analyses were performed with
Prism 6 for Macintosh (Graphpad Software, San Diego,
CA) and SAS 9.3 for Windows (SAS Institute, Cary, NC);
some graphs were drawn with S-Plus 8.2.
Additional file
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